Sanofi Enters the M&A Game with a $1.7B Acquisition

Continued up and down performance for the market into the week ending January 19th. Sanofi jumped into the M&A game with a $1.7B acquisition of Inhibrx:

Week Ending January 19th, 2024

• Biotech: 6 Transactions (6 Follow-Ons) totaling just over $800 Million

• Med Tech: No Current Week Transactions

2024 YTD:

• 18 Biotech transactions totaling just under $3 Billion v. 2023: 4 Biotech transaction totalings just under $600 Million

• 1 Med Tech transaction totaling $50 Million v. 2023: 0 Med Tech transactions

Private Transactions:

• Biotech: 13 US Transactions / 9 European Transactions

• Med Tech: 9 US Transactions / 4 European Transaction

M&A Deals:

• Sanofi acquired Inhibrx for $1.7B or $30/share